The targeting of FGF/FGFR has become the most promising approach to treating patients with advanced/metastatic CCA.7 FGFRs are a family of receptor tyrosine kinase (TK) which may be upregulated in many tumor cell types and may contribute to tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.8,9 Understanding the pathogenic mechanisms resulting from mutations, gene fusions, and gene amplifications in FGFs and FGFRs has led to therapeutic approaches for different type of cancers. The gene discussed is TKT; the disease is neoplasm.